Type 2 diabetes

Chatterjee, Sudesna; Khunti, Kamlesh; Davies, Melanie J.

doi:10.1016/s0140-6736(17)30058-2

Cited by 2,038 publications

(1,603 citation statements)

References 136 publications

Supporting

Mentioning

1,540

Contrasting

Unclassified

Order By: Relevance

“…However, 318 million people have a preclinical state of impaired glucose regulation [104,105], but intensive pharmacotherapy modifies the patient's lifestyle, since it can reverse or delay the development of T2DM [106,107]. In humans, obesity is the most common cause for developing insulin resistance, which is a key component in the etiology of T2DM [108,109].…”

Section: Type 2 Diabetes Mellitus and Obesitymentioning

confidence: 99%

Adipose Tissue and Inflammation

Muñoz‐Carrillo¹,

Campo²,

Coronado³

et al. 2018

Adipose Tissue

View full text Add to dashboard Cite

Adipose tissue is composed mainly by adipocytes and stromal-vascular fraction, which are composed by different cell types including macrophages. There are three types of adipose tissue: brown (BrAT), white (WAT), and beige (BeAT). BrAT is less abundant and is implicated in lipid oxidation and energy balance; BeAT has the pathway of adaptive thermogenesis, and WAT is endocrine in nature and lipid storage site and is implicated as an endocrine organ that secretes hormones and different molecules. These molecules are pro-inflammatory and anti-inflammatory factors, including the adipokines leptin, adiponectin, resistin, and visfatin, as well as cytokines and chemokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, leptin, adiponectin, and others, are involved with the development of adipose tissue inflammation and obesity. This pathological condition, together with other factors such as oxidative stress, may develop insulin resistance and the pathogenesis of type 2 diabetes mellitus (T2DM).

show abstract

Section: Type 2 Diabetes Mellitus and Obesitymentioning

confidence: 99%

Adipose Tissue and Inflammation

Muñoz‐Carrillo¹,

Campo²,

Coronado³

et al. 2018

Adipose Tissue

View full text Add to dashboard Cite

show abstract

“…Cuando se administra de forma crónica, puede presentarse una menor secreción de insulina, esto debido a un fenómeno de regulación a la baja del receptor SUR en la célula β, efecto que desaparece luego de la suspensión por un período este medicamento 22 . Es de bajo costo y se ha asociado con aumento de peso (en promedio 2 Kg) e hipoglucemia 23 .…”

Section: Sulfonilureas -Glicazida Glimepiride Tolbutamide Gliquidounclassified

“…Se puede usar en pacientes que requieren un hipoglucemiante de corta acción como en aquellos que tienen un patrón de hiperglucemia postprandial 23 .…”

Section: Meglitinidas -Repaglinida Nateglinidaunclassified

Enfoque terapéutico de la diabetes mellitus tipo 2 en adultos. Más allá de una meta glucémica

Betancur

2018

MedUPB

View full text Add to dashboard Cite

Enfoque terapéutico de la diabetes mellitus tipo 2 en adultos. Más allá de una meta glucémicaTherapeutic approach to type 2 diabetes mellitus in adults: Beyond a glycemic goal / Enfoque terapêutico da diabetes mellitus tipo 2 em adultos. Além de uma meta glicêmica Santiago Saldarriaga Betancur 1 RESUMEN La diabetes mellitus tipo 2 es una enfermedad que cada día incrementa su incidencia y prevalencia. Se estima que más de 400 millones de personas tienen esta enfermedad y muchos desconocen su diagnóstico. La diabetes mellitus produce desenlaces microvasculares y macrovasculares desfavorables. A lo largo de los años se ha encontrado que el control intensivo de la glucemia tiene beneficios sobre los desenlaces microvaculares; sin embargo, no se había logrado demostrar desenlaces macrovasculares satisfactorios hasta los últimos años cuando gracias a nuevas moléculas se demostró dicho beneficio. Es por esto que el enfoque terapéutico de la diabetes mellitus tipo 2 ha cambiado, ahora no solo es lograr una meta en hemoglobina glicada (HbA1c), sino también lograr disminuir el riesgo cardiovascular con el objetivo de disminuir eventos micro y especialmente macrovasculares. En los últimos años se han identificado nuevas dianas terapéuticas para el tratamiento de esta entidad, con el desarrollo de moléculas que además de haber demostrado un control glucémico aceptable, también representan seguridad cardiovascular, incluso algunas han confirmado disminuir el riesgo cardiovascular. A lo largo del artículo se discute la importancia del riesgo cardiovascular en la población con diabetes mellitus tipo 2 y los esquemas terapéuticos disponibles para impactar sobre este riesgo. Palabras clave: diabetes mellitus; enfermedades cardiovasculares; terapéutica. ABSTRACTThe incidence and prevalence of type 2 diabetes mellitus increase daily. It is estimated that more than 400 million people have this disease and many are unaware of it. Diabetes mellitus produces unfavorable microvascular and macrovascular outcomes. Over the years it has been found that intensive glycemic control has benefits over microvascular outcomes; however, it had not been possible to demonstrate satisfactory macrovascular outcomes until recent years when, thanks to new molecules, this benefit has been demonstrated. This is why the therapeutic approach of type 2 diabetes mellitus has changed, and no longer consists in simply achieving a goal in glycated hemoglobin (HbA1c), but also in reducing cardiovascular risk with the aim of decreasing micro and especially macrovascular events. In recent years, new therapeutic targets have been identified for the treatment of this entity, with the development of molecules that have demonstrated an acceptable glycemic control as well as cardiovascular safety; some have even been shown to decrease cardiovascular risk. This article discusses the importance of cardiovascular risk in people with type 2 diabetes mellitus and therapeutic options that have an impact on this risk.

show abstract

“…There is an intense focus on the evidence base for optimal T2DM management with the ability to deliver effective multidisciplinary care after early diagnosis and initiate effective glucoselowering therapies supported by structured education and selfmanagement programs [92].The European Association for the Study of Diabetes (Inzucchi, Bergenstal et al 2015) and American Diabetes Association adopted a patient-centered approach that includes optimizing therapeutic options across the life spanthe Chronic Care Model (CCM) for prevention and treatment of T2DM. A major barrier to optimal care is a delivery system that is often fragmented, lacks clinical information capabilities, duplicates services, and is poorly designed for the coordinated delivery of chronic care [93].…”

Section: Contemporary Treatment Options For T2dmmentioning

confidence: 99%

“…New technologies and therapeutic options for T2DM patients are being extensively investigated [92]. Well-tolerated treatments that produce a long-lasting impact on IR are in great demand.…”

Section: The Need For New Therapeutic Agentsmentioning

confidence: 99%

Can Avicenna Help Manage the Diabetes Epidemic in Central Asia?

Sharofova,

Nuraliev,

Sukhrobov

et al. 2017

Cent. Asian j. Med. Sci.

View full text Add to dashboard Cite

Objectives:The fast-rising rate of diabetes incidents is a growing concern in Central Asian countries. This article reviews the current understanding of type 2 diabetes etiology, progression and treatment options along with opportunities for utilizing Avicenna's legacy in developing novel botanical therapeutics. Methods: Analysis of relevant publications, including a variety of Avicenna's work in Arabic, English and Russian. Results: With conventional treatment strategy shifting from single-component drugs aimed at one target to multitherapeutic combinations addressing the complex nature of many diseases and conditions, the role of multicomponent botanical preparations may increase. Diabetes mellitus is a serious chronic, progressive disease characterized by hyperglycemia, which is associated with a variety of comorbidities because of considerable damage, dysfunction and failure of multiple organs developed through the disease's progression. Multidisciplinary collaborative research that encompasses innovative tools could be used for effective development of new comprehensive therapeutic products and treatments based on knowledge of traditional medicine and supported by contemporary scientific validation. Conclusion: Comprehensive analysis of Avicenna's 1,000-year-old approach to the treatment of prediabetes and diabetes provides valuable directions in the search for plant-based treatments. Botanical therapeutics may provide relatively inexpensive and safe methods for diabetes treatment.

show abstract

Type 2 diabetes

Cited by 2,038 publications

References 136 publications

Adipose Tissue and Inflammation

Adipose Tissue and Inflammation

Enfoque terapéutico de la diabetes mellitus tipo 2 en adultos. Más allá de una meta glucémica

Can Avicenna Help Manage the Diabetes Epidemic in Central Asia?

Contact Info

Product

Resources

About